Semax (ACTH Fragment Peptide)

Semax Mechanism: Neurotrophin Expression

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

The principal reported mechanism is upregulation of neurotrophin gene expression. Rodent studies have reported increased BDNF and NGF expression in hippocampus and frontal cortex, with downstream signalling through the TrkB and TrkA receptors. Additional reported activity includes dopaminergic and serotonergic modulation.

Key facts

Primary reported targets
BDNF, NGF
Downstream receptors
TrkB (BDNF), TrkA (NGF)
Regions studied
Hippocampus, frontal cortex
Model organism
Rat
Key reference
Brain Res 2006 (PMID 16996037)
Also reported
Dopaminergic, serotonergic modulation
Steroidogenic activity
None (unlike parent ACTH)

What neurotrophins are

Brain-derived neurotrophic factor and nerve growth factor are growth factors that support neuronal survival, differentiation and synaptic plasticity. BDNF signals through the TrkB receptor, NGF through TrkA. Both are involved in activity-dependent plasticity, which is why expression changes in these genes attract attention in cognitive and neuroprotection research.

What the studies actually measured

The 2003 Doklady Biological Sciences paper reported that Semax stimulates BDNF expression across regions of the rat brain in vivo. The 2006 Brain Research study reported regulation of both BDNF and trkB expression in the rat hippocampus. A 2010 Journal of Molecular Neuroscience paper compared the temporal dynamics of NGF and BDNF gene expression across hippocampus and frontal cortex. These are gene- and protein-expression measurements in rodents, not behavioural or clinical endpoints.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Expression is upstream of effect

This distinction is worth holding onto. Demonstrating that a compound raises BDNF messenger RNA in rat hippocampus establishes that it does something measurable to that pathway. It does not by itself establish a functional consequence, and it certainly does not establish one in a different species. The gap between an expression change and an outcome is where a great deal of peptide literature quietly overreaches.

The wider transcriptional picture

A 2014 BMC Genomics study took a broader approach, reporting that Semax affects expression of genes related to the immune and vascular systems in a rat model of focal cerebral ischaemia. That is a considerably wider signature than neurotrophins alone, and it suggests the compound's transcriptional effects are not confined to a single pathway.

What separates it from ACTH

The parent hormone acts on melanocortin receptors and stimulates adrenal steroidogenesis. Semax does not, because the residues responsible were replaced by Pro-Gly-Pro. Whatever central activity the peptide has is therefore not secondary to a corticosteroid response, which is the main confound the design was intended to eliminate.

What remains unresolved

No receptor has been definitively established as the primary target. The mechanistic literature describes downstream consequences (expression changes, neurotransmitter modulation) more confidently than it describes the initiating molecular event. That is a real gap, not a summary omission.

Frequently asked questions

Does Semax have a known receptor?

No primary receptor has been definitively established. The literature characterises downstream effects more clearly than the initiating interaction.

Were the BDNF studies done in humans?

No. The neurotrophin expression work is rodent, principally rat hippocampus and frontal cortex.

Does Semax raise cortisol like ACTH?

No. The Pro-Gly-Pro substitution removes the steroidogenic activity of the parent hormone.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.